Eigen Value Analysis of HIV-1 Integrase Inhibitors

Journal of Chemical Information and Computer Sciences

Volumn 41, Issue 6, 2001, Pages 1569-1577

  Makhija, Mahindra T ^a   Kulkarni, Vithal M ^a  

^a UNIVERSITY OF MUMBAI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; INTEGRASE INHIBITOR;

ARTICLE; CHEMISTRY; CONFORMATION; DRUG EFFECT; REGRESSION ANALYSIS;

HIV INTEGRASE; HIV INTEGRASE INHIBITORS; LEAST-SQUARES ANALYSIS; MOLECULAR CONFORMATION; SUPPORT, NON-U.S. GOV'T;

RETROVIRUSES;

CATALYSIS; CHEMOTHERAPY; EIGENVALUES AND EIGENFUNCTIONS; FREQUENCIES; IMMUNOLOGY; SYNTHESIS (CHEMICAL); VIRUSES;

ENZYME INHIBITION;

EID: 0035498338     PISSN: 00952338     EISSN: None     Source Type: Journal    
DOI: 10.1021/ci0001334     Document Type: Article

References (44)

1. De Clercq, E. Toward improved anti-HIV chemotherapy. Therapeutic strategies for intervention with HIV infection. J. Med. Chem. 1995, 38, 2491-2517.
2. Hariprasad, V.; Talele, T. T.; Kulkarni, V. M. Design and synthesis of a novel series of nonpeptidic HIV-1 protease inhibitors, Pharm. Pharmacol. Commun. 1998, 4, 365-372.
3. Sakai, H.; Kawamura, M.; Sakuragi, J.; Sakuragi, S.; Shibata, R.; Ishimoto, A.; Ono, H.; Ueda, S.; Adachi, A. Integration is essential for efficient gene expression of human immunodeficiency virus type 1. J. Virol. 1993, 7, 1169-1174.
4. Taddeo, B.; Haseltine, W. A.; Farnet, C. M. Integrase mutants of human immunodeficiency virus type 1 with a specific defect in integration. J. Virol. 1994, 68, 8401-8405.
5. Engelman, A.; Englund, G.; Orenstein, J. M.; Martin, M. A.; Craigie, R. Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J. Virol. 1995, 69, 2729-2736.
6. Goff, S. P. Genetics of retroviral integration. Annu. Rev. Genet. 1992, 26, 527-544.
7. Craigie, R. Hotspots and Warm spots: Integration Specificity of Retroelements. Trends Genet. 1992, 8, 187-190.
8. Pommier, Y.; Pilon, A.; Bajaj, K.; Mazumder, A.; Neamati, N. HIV-1 integrase as a target for antiviral drugs. Antiviral Chem. Chemother. 1997, 8, 483-503.
9. Neamati, N.; Sunder, S.; Pommier, Y. Design and discovery of HIV-1 integrase inhibitors. Drug Discovery Today 1997, 2, 487-498.
10. Stanwell, C.; Ye, B.; Yuspa, S. H.; Burke, T. R., Jr. Cell protein cross-linking by erbstatin and related compounds. Biochem. Pharmacol. 1996, 52, 475-480.
11. Neamati, N.; Hong, H.; Owen, J. M.; Sunder, S.; Winslow, H. E.; Christensen, J. L.; Zhao, H.; Burke, T. R., Jr; Milne, G. W. A., Pommier, Y. Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site. J. Med. Chem. 1998, 41, 3202-3209.
12. Neamati, N.; Hong, H.; Mazumder, A.; Wang, S.; Sunder, S.; Nicklaus, M. C.; Milne, G. W. A.; Proksa, B.; Pommier, Y. Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. J. Med. Chem. 1997, 40, 942-951.
13. Zhao, H.; Neamati, N.; Hong, H.; Mazumder, A.; Wang, S.; Sunder, S.; Milne, G. W. A.; Pommier, Y.; Burke, T. R., Jr. Coumarin-based inhibitor of HIV integrase. J. Med. Chem. 1997, 40, 242-249.
14. Mazumder, A.; Wang, S.; Neamati, N.; Nicklaus, M.; Sunder, S.; Chen, J.; Milne, G. W. A.; Rice, W. G.; Burke, T. R., Jr.; Pommier, Y. Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease. J. Med. Chem. 1996, 39, 2472-2481.
15. Zhao, H. Neamati, N.; Sunder, S.; Hong, H.; Wang, S.; Milne, G. W. A.; Pommier, Y.; Burke, T. R., Jr. Hydrazide-containing inhibitors of HIV-1 integrase. J. Med. Chem. 1997, 40, 937-941.
16. Neamati, N.; Turpin, J. A.; Winslow, H. E.; Christensen, J. L.; Williamson, K.; Orr, A.; Rice, W. G.; Pommier, Y.; Garofalo, A.; Brizzi, A.; Campiani, G.; Fiorini, I.; Nacci, V. Thiazolothiazepine inhibitors of HIV-1 integrase. J. Med. Chem. 1999, 42, 3334-3341.
17. Cramer, R. D., III.; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
18. Kulkarni, S. S.; Kulkarni, V. M. Three-dimensional quantitative structure activity relationships of interleukin 1β converting enzyme inhibitors: a comparative molecular field analysis study. J. Med. Chem. 1999, 42, 373-380.
19. Gokhale, V. M. Kulkarni, V. M. Comparative molecular field analysis of fungal squalene epoxidase inhibitors. J. Med. Chem. 1999, 42, 5348-5358.
20. Talele, T. T.; Kulkarni, S. S.; Kulkarni, V. M. Development of pharmacophore alignment models as input for comparative molecular field analysis (CoMFA) of azole antifungal agents. J. Chem. Inf. Camput. Sci. 1999, 39, 958-966.
21. Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 1994, 37, 4130-4146.
22. Klebe, G. Comparative molecular similarity indices analysis: CoMSIA. Perspect Drug Discovery Des. 1998, 12, 87-104.
23. Bohm, M.; Sturzebecher, J.; Klebe, G. Three-dimensional quantitative structure activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin and factor Xa. J. Med. Chem. 1999, 42, 458-477.
24. Makhija, M. T.; Kulkarni, V. M. 3D QSAR and molecular modeling of HIV-1 integrase inhibitors. J. Comput.-Aided Mol. Des. 2001, (Communicated).
25. Wagener, M.; Sadowski, J.; Gasteiger, J. Autocorrelation of molecular surface properties for modeling corticosteroid binding globulin and cytosolic Ah receptor activity by neural networks. J. Am. Chem. Soc. 1995, 117, 7769-7775.
26. Silverman, B. D.; Platt, D. E. Comparative molecular moment analysis (CoMMA): 3D QSAR without molecular superposition. J. Med. Chem. 1996, 39, 2129-2140.
27. Bravi, G.; Gancia, E.; Mascagni, P.; Pegna, M.; Todeschini, R.; Zaliani, A. MS-WHIM, new 3D theoretical descriptors derived from molecular surface properties: A comparative 3D QSAR study in a series of steroids. J. Comput.-Aided Mol. Des. 1997, 11, 79-92.
28. Ferguson, A. M.; Heritage, T.; Jonathon, P.; Pack, S. E.; Phillips, L.; Rogan, J.; Snaith, P. J. EVA: A new theoretically based molecular descriptor for use in QSAR/QSPR analysis. J. Comput.-Aided Mol. Des. 1997, 11, 143-152.
29. Turner, D. B.; Willett, P.; Ferguson, A. M.; Heritage, T. Evaluation of a novel infrared range vibration-based descriptor (EVA) for QSAR studies, 1. General application. J. Comput.-Aided Mol. Des. 1997, 11, 409-422.
30. Turner, D. B.; Willett, P. The EVA spectral descriptor. Eur. J. Med. Chem. 2000, 35, 367-375.
31. SYBYL Ligand-Based Design Manual version 6.6; Tripos, Inc.: St. Louis, MO, 1999.
32. Turner, D. B.; Willett, P.; Ferguson, A. M.; Heritage, T. W. Evaluation of a novel molecular vibration-based descriptor (EVA) for QSAR studies: 2. Model validation using a benchmark steroid dataset. J. Comput.-Aided Mol. Des. 1999, 13, 271-296.
33. Ginn, R. M. C.; Turner, D. B.; Willett, P. Similarity searching in files of three-dimensional chemical structures: Evaluation of the EVA descriptor and combination of rankings using data fusion. J. Chem. Inf. Comput. Sci. 1997, 37, 23-37.
34. Heritage, T. W.; Ferguson, A. M.; Turner, D. B.; Willett, P. EVA: A novel theoretical descriptor for QSAR studies. Perspect Drug Discovery Des. 1998, 381-398.
35. SYBYL Molecular Modeling System, version 6.6; Tripos, Inc.: St. Louis, MO.
36. Clark, M.; Cramer, R. D., III.; Van Opdenbosh, N. Validation of the General-Purpose Tripos 5.2 force field. J. Comput. Chem. 1989, 10, 982-1012.
37. MOPAC 6.0 is available from Quantum Chemistry Program Exchange, Indiana University.
38. Stewart, J. J. P. MOPAC: a semiempirical molecular orbital program. J. Comput.-Aided Mol. Des. 1990, 4, 1-103.
39. Wold, S.; Albano, C.; Dunn, W. J., III.; Edlund, U.; Esbensen, K.; Geladi, P.; Hellberg, S.; Johansson, E.; Lindberg, W.; Sjostrom, M. Multivariate Data Analysis in Chemistry. In CHEMOMETRICS: Mathematics and Statistics in Chemistry; Kowalski, B., Ed.; Reidel: Dordrecht, The Netherlands, 1984.
40. Bush, B. L.; Nachbar, R. B., Jr. Sample-distance partial least squares: PLS optimised for many variables, with application to CoMFA. J. Comput.-Aided Mol. Des. 1993, 7, 587-619.
41. Waller, C. L.; Oprea, T. L.; Giolliti, A.; Marshall, G. R. Three-dimensional QSAR of human immunodeficiency virus (1) protease inhibitors. 1. A CoMFA stud employing experimentally determined alignment rules. J. Med. Chem. 1993, 36, 4152-4160.
42. Cramer, R. D., III.; Bunce, J. D.; Patterson, D. E. Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant. Struct. Act. Relat. 1988, 7, 18-25.
43. Makhija, M. T.; Kulkarni, V. M. Molecular electrostatic potentials as input for the alignment of HIV-1 integrase inhibitors in 3D QSAR. J. Comput.-Aided Mol. Des. 2001, in press.
44. Goldgur, Y.; Craigie, R.; Cohen, H. G.; Fujiwara, T.; Yoshinaga, T.; Fujishita, T.; Sugimoto, H.; Endo, T.; Murai, H.; Davies, R. D. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 13040-13043.